Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.39 |
| ▸ | CDC7 | O00311 | 3/20 | 0.39 |
| ▸ | PIM1 | P11309 | 3/20 | 0.39 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | PRKACA | P17612 | 2/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 6/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1835853 | 0.85 | GSK3B (0.39) | GSK3BCDC7PIM1HIPK2CLK4 | |
| SCHEMBL1839402 | 0.83 | PRKDC (0.54) | GSK3BCDC7PIM1HIPK2CLK4 | |
| Oxalic Acid SCHEMBL1835999 | 0.82 | CYP2C9 (0.41) | GSK3BCDC7PIM1HIPK2CLK4 | |
| SCHEMBL1960579 | 0.81 | GSK3B (0.40) | GSK3BCDC7PIM1HIPK2CLK4 | |
| Fumaric Acid SCHEMBL1960107 | 0.77 | CYP3A4 (0.39) | GSK3BCDC7PIM1HIPK2CLK4 | |
| Maleic Acid SCHEMBL1960105 | 0.77 | CYP3A4 (0.39) | GSK3BCDC7PIM1HIPK2CLK4 | |
| SCHEMBL1838129 | 0.73 | GSK3B (0.41) | GSK3BCDC7PIM1HIPK2CLK4 | |
| SCHEMBL1839427 | 0.73 | GSK3B (0.45) | GSK3BCDC7PIM1HIPK2CLK4 | |
| SCHEMBL910196 | 0.71 | GSK3B (0.46) | GSK3BCDC7PIM1HIPK2CLK4 | |
| SCHEMBL1840729 | 0.71 | GAA (0.43) | GSK3BCDC7PIM1HIPK2CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321313-B1 | SUBSTITUTED PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE DERIVATIVES AS GSK3 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-09-02 | — | — | EP | claimed |
| US-8211903-B2 | Substituted pyrimido isoquinoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-03 | — | — | US | claimed |
| US-20110144138-A1 | SUBSTITUTED PYRIMIDO ISOQUINOLINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | claimed |
| EP-2321313-A1 | SUBSTITUTED PYRIMIDO [2, 1-A]ISOQUINOLIN-4-ONE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-05-18 | — | — | EP | claimed |
| EP-2138495-A1 | Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives | sanofi-aventis (FR) | 2009-12-30 | — | — | EP | claimed |
| WO-2009156859-A1 | SUBSTITUTED PYRIMIDO [2, 1-A] ISOQUINOLIN-4-ONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-12-30 | — | — | WO | claimed |
| US-8211903-B2 | Substituted pyrimido isoquinoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20110144138-A1 | SUBSTITUTED PYRIMIDO ISOQUINOLINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| EP-2321313-A1 | SUBSTITUTED PYRIMIDO [2, 1-A]ISOQUINOLIN-4-ONE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-05-18 | — | — | EP | disclosed |
| EP-2138495-A1 | Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives | sanofi-aventis (FR) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009156859-A1 | SUBSTITUTED PYRIMIDO [2, 1-A] ISOQUINOLIN-4-ONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144138-A1 | SUBSTITUTED PYRIMIDO ISOQUINOLINE DERIVATIVES | RECQL, QDPR, IFNAR1 | GSK3B 4110/4885CDC7 1008/4885PIM1 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.